STOCKHOLM, February 16, 2010. Karo Bio AB (publ) (Reuters: KARO. ST) today announced that Per Olof Wallström, President and CEO of Karo Bio AB for the past five years, has decided to resign to pursue other opportunities. He intends to stay with the company until his successor has been appointed. "P. O. has been a dedicated and effective leader of our company", said Dr. Leon Rosenberg, Chair of...

STOCKHOLM, December 30, 2009. Karo Bio AB (publ) (Reuters: KARO. ST) today announced that the company’s total number of shares as per December 30, 2009 amounts to 154, 825, 589 shares, corresponding to an equal number of votes. The increase in the number of shares and votes results from an issue of 38, 706, 397 shares under Karo Bio’s rights issue that was announced on October 26, 2009. For more...

Not for release, publication or distribution in Australia, Canada, Japan or the United States. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities of Karo Bio AB (publ) (the “Securities”) in Australia, Canada, Japan or the United States or in any other jurisdiction. Securities may not be offered or sold in the United States absent...

Not for release, publication or distribution in Australia, Canada, Japan or the United States. This announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities of Karo Bio AB (publ) (the “Securities”) in Australia, Canada, Japan or the United States or in any other jurisdiction. Securities may not be offered or sold in the United States absent...

STOCKHOLM, SWEDEN, November 26, 2009. The Swedish biotech company Karo Bio (Reuters: KARO. ST) today announced that Merck & Co., Inc., through an affiliate, plans to enter a clinical phase IIa trial with the collaboration's lead investigational drug candidate, MK-6913, identified as part of their joint research collaboration. No milestone payment to Karo Bio is associated with the initiation of...